Australia markets closed

Pharmaxis Ltd (PMXSF)

Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
0.0784-0.0166 (-17.47%)
At close: 9:53AM EDT
Full screen
Trade prices are not sourced from all markets
Previous close0.0950
BidN/A x N/A
AskN/A x N/A
Day's range0.0784 - 0.0784
52-week range0.0784 - 0.0784
Avg. volume0
Market cap39.424M
Beta (5Y monthly)0.43
PE ratio (TTM)N/A
EPS (TTM)-0.0050
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • PR Newswire

    Pharmaxis Treatment to Prevent Wound and Burns Scars Clears Phase 1 Trial

    Pharmaxis (ASX: PXS) today announced that its novel topical drug treatment for scarring has delivered positive Phase 1 clinical trial results and will now advance to the next stage of development in patients. In a study of healthy volunteers led by renowned surgeon Prof Fiona Wood AM the Pharmaxis drug demonstrated good tolerability and full inhibition of the enzymes being targeted to prevent scarring.

  • PR Newswire

    Pharmaxis Cancer Drug Decreases Tumour Burden in Pre Clinical Liver Cancer Model

    Clinical stage drug development company Pharmaxis Ltd (ASX: PXS) today announced the first public presentation of data from a preclinical study of PXS-5505 in the liver cancer, cholangiocarcinoma (CCA) at the Americas Hepato-Pancreato-Biliary Association (AHBPA) conference in Miami, USA.

  • PR Newswire

    Pharmaxis Commences Final Cohort Dosing in Bone Marrow Cancer Phase 1c Trial

    Clinical stage drug development company Pharmaxis Ltd (ASX: PXS) today announced results of data analysis from the second of three stages in its phase 1c clinical trial (MF-101) studying a potential new treatment for the bone marrow cancer myelofibrosis. The increase in dose lead to a predictable increase in drug blood levels in patients and showed the same good tolerability seen in the first dose cohort.